熱門資訊> 正文
FDA批准Illumina的TruSight肿瘤生物标志物测试
2024-08-28 05:12
- The FDA has approved Illumina’s (NASDAQ:ILMN) TruSight Oncology Comprehensive biomarker test and two companion diagnostic indications.
- TruSight was approved as a companion diagnostic to identify adults and children with solid tumors who are positive for NTRK gene fusions and may benefit from Bayer’s drug Vitrakvi, also known as larotrectinib.
- The diagnostic was also approved to identify adults with advanced or metastatic RET fusion-positive non-small cell lung cancer who may benefit from Eli Lilly’s (LLY) Retevmo, or selpercatinib.
- The company will begin shipping TruSight Oncology Comprehensive to customers later this year, Illumina added in a statement.
- A CE-marked version of the product has been available in Europe since 2022.
More on Illumina
- Illumina Sees The Light: GRAIL Is Gone, Focus Restored (Rating Upgrade)
- Illumina Looks Bullish (Technical Analysis)
- Illumina, Inc. (ILMN) Illumina 2024 Strategy Update Special Call
- ValueAct exits CBRE stake, adds to Disney stake, among Q2 buys/sells
- Illumina upgraded at Barclays as investor day gives 'solid framework' for future
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
